Cidara Therapeutics Announces Promotion of Taylor Sandison, M.D., M.P.H., to Chief Medical Officer
April 25 2017 - 8:30AM
Business Wire
Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology
company developing novel anti-infectives including immunotherapies,
today announced that Taylor Sandison, M.D., M.P.H., has been named
chief medical officer (CMO) of the company. Dr. Sandison has been
serving as acting chief medical officer of Cidara since September
2016. As CMO, he will continue to lead the global clinical
development of CD101 IV, Cidara’s novel echinocandin antifungal,
currently in Phase 2 clinical trials, as well as the expanding
pipeline of anti-infective candidates generated by the company’s
Cloudbreak™ immunotherapy platform.
“Dr. Sandison’s depth and breadth of experience in
anti-infective clinical development has been tremendously valuable
to Cidara,” said Jeffrey Stein, Ph.D., president and chief
executive officer of Cidara. “We are fortunate to have his clinical
leadership as we advance our portfolio of drug candidates to treat
serious fungal and bacterial infections.”
Dr. Sandison has been with Cidara since October 2015, first
serving as the company’s senior medical director. Prior to joining
Cidara, he served as senior medical director at Cubist
Pharmaceuticals, Inc. from July 2014 to January 2015 and then,
following Merck’s acquisition of Cubist, as senior medical director
at Merck from February to October 2015. Dr. Sandison also has held
positions at Trius Therapeutics and Novartis Diagnostics, and
served as a faculty member in the Department of Medicine at both
Stanford University and the University of Washington.
Dr. Sandison received B.S. and B.A. degrees from Dartmouth
College, and M.D. and M.P.H. degrees from the University of
Washington. He completed residency training at the University of
Colorado and fellowship training at the University of Washington,
and holds board certifications in both infectious diseases and
internal medicine.
About Cidara Therapeutics
Cidara is a clinical-stage biotechnology company focused on
developing new anti-infectives that have the potential to transform
the standard of care and save or improve patients’ lives. The
company is currently advancing its novel echinocandin antifungal,
CD101 IV, through Phase 2 clinical trials and is developing CD201,
a bispecific immunotherapy, for the treatment of multi-drug
resistant Gram-negative bacterial infections. CD101 IV has improved
pharmacokinetics and expanded utility across patient
settings compared to existing echinocandins. CD101 IV is the
only once-weekly therapy intended for the treatment and prevention
of life-threatening invasive fungal infections. CD201 is the first
drug candidate selected from Cidara’s novel Cloudbreak™
immunotherapy platform and is designed to specifically direct a
patient’s immune cells to attack and kill bacterial pathogens.
Cidara recently received a grant for up to $6.9 million from CARB-X
(Combating Antibiotic Resistant Bacteria Accelerator) to advance
the development of CD201. Cidara is headquartered in San Diego,
California. For more information, please visit www.cidara.com.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Such
statements include, but are not limited to, statements regarding
the effectiveness, safety, and other attributes of CD101 and CD201
and other potential product candidates, including the potential for
these compounds to successfully treat fungal or bacterial
infections, including those caused by resistant pathogens, and
potentially transform the way infectious diseases are treated, and
the potential for the Cloudbreak platform to result in future drug
candidates. Risks that contribute to the uncertain nature of the
forward-looking statements include: the success and timing of
Cidara’s preclinical studies and clinical trials; regulatory
developments in the United States and foreign countries; changes in
Cidara’s plans to develop and commercialize its product candidates;
Cidara’s ability to obtain additional financing; Cidara’s ability
to obtain and maintain intellectual property protection for its
product candidates; and the loss of key scientific or management
personnel. These and other risks and uncertainties are described
more fully in Cidara’s Form 10-K most recently filed with the
United States Securities and Exchange Commission. All
forward-looking statements contained in this press release speak
only as of the date on which they were made. Cidara undertakes no
obligation to update such statements to reflect events that occur
or circumstances that exist after the date on which they were
made.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170425005275/en/
Cidara Therapeutics, Inc.INVESTOR CONTACT:Westwicke
Partners, LLCRobert H. Uhl, 858-356-5932Managing
Directorrobert.uhl@westwicke.comorMEDIA CONTACT:Sam Brown
Inc.Christy Curran, 615-414-8668ChristyCurran@sambrown.com
Cidara Therapeutics (NASDAQ:CDTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cidara Therapeutics (NASDAQ:CDTX)
Historical Stock Chart
From Apr 2023 to Apr 2024